Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors

Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors

Abstract Background Chiauranib is a novel orally active multi-target inhibitor that simultaneously inhibits the angiogenesis-related kinases (VEGFR2, VEGFR1, VEGFR3, PDGFRα, and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R. This phase I dose-escalation stud...

Full description

Bibliographic Details
Main Authors: Yongkun Sun, Lin Yang, Xuezhi Hao, Yutao Liu, Jinwen Zhang, Zhiqiang Ning, Yuankai Shi
Format: Article
Language:English
Published: BMC 2019-01-01
Series:Journal of Hematology & Oncology
Subjects:
Advanced solid tumors
Chiauranib
Dose-escalation
Pharmacokinetics
Phase I study
Safety
Online Access:http://link.springer.com/article/10.1186/s13045-018-0695-0

Internet

http://link.springer.com/article/10.1186/s13045-018-0695-0

Similar Items